Canada Markets closed

ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.35000.0000 (0.00%)
At close: 4:00PM EDT
1.3400 -0.01 (-0.74%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.3500
Open1.4000
Bid1.3400 x 4000
Ask1.3800 x 4000
Day's Range1.3200 - 1.4100
52 Week Range1.0100 - 3.1110
Volume2,313,702
Avg. Volume3,276,634
Market Cap173.056M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.7750
Earnings DateNov. 03, 2021 - Nov. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.60
  • GlobeNewswire

    ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an ad

  • GlobeNewswire

    ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference. The abstract and poster present

  • GlobeNewswire

    ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, resulting in gross proceeds of approximately $50 million before deducting